Zhu Chenglou, Ji Dandan, Ma Jichun, Da Mingxu
The First School of Clinical Medicine, Lanzhou University, Lanzhou, China.
The First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, China.
Oncology. 2024;102(6):533-543. doi: 10.1159/000534812. Epub 2023 Nov 2.
In this study, clinical trials were generalized, summarized, and meta-analyzed to evaluate correlations between artificial sweeteners (ASs) and colorectal cancer (CRC). PubMed, Web of Science, Embase (Ovid platform), MEDLINE, and the Cochrane Library databases were searched from inception until July 24, 2023. The association between AS exposure and CRC incidence was assessed using odds ratios (ORs) and 95% confidence intervals (CIs). STATA software (version 12.0) was used to perform the meta-analysis. Ten studies (three case-control studies and seven cohort studies) involving 711,537 participants were identified. Results showed that the intake of ASs reduced the incidence of CRC (OR = 0.93, 95% CI = [0.87-0.99]) and was not significantly associated with mortality (OR = 0.93, 95% CI = [0.83-1.05]). Subgroup analyses showed that low doses of ASs were associated with lower CRC incidence (OR = 0.90, 95% CI = [0.83-0.99]), and medium/high doses were not associated with CRC incidence (OR = 1.11, 95% CI = [0.93-1.33]; OR = 0.89, 95% CI = [0.79-1.00], respectively). Moreover, low, medium, and high exposures were not associated with an increased risk of mortality due to CRC (OR = 0.95, 95% CI = [0.80-1.14]; OR = 0.99, 95% CI = [0.88-1.11]; OR = 0.93, 95% CI = [0.71-1.21], respectively). The results of our meta-analysis showed that a low intake of ASs may be associated with a lower risk of CRC.
在本研究中，对临床试验进行了归纳、总结和荟萃分析，以评估人工甜味剂（ASs）与结直肠癌（CRC）之间的相关性。检索了PubMed、Web of Science、Embase（Ovid平台）、MEDLINE和Cochrane图书馆数据库，检索时间从建库至2023年7月24日。使用比值比（ORs）和95%置信区间（CIs）评估AS暴露与CRC发病率之间的关联。使用STATA软件（版本12.0）进行荟萃分析。确定了10项研究（3项病例对照研究和7项队列研究），涉及711,537名参与者。结果显示，ASs的摄入降低了CRC的发病率（OR = 0.93，95% CI = [0.87 - 0.99]），且与死亡率无显著关联（OR = 0.93，95% CI = [0.83 - 1.05]）。亚组分析显示，低剂量的ASs与较低的CRC发病率相关（OR = 0.90，95% CI = [0.83 - 0.99]），而中/高剂量与CRC发病率无关（OR分别为1.11，95% CI = [0.93 - 1.33]；OR = 0.89，95% CI = [0.79 - 1.00]）。此外，低、中、高暴露与CRC导致的死亡风险增加无关（OR分别为0.95，95% CI = [0.80 - 1.14]；OR = 0.99，95% CI = [0.88 - 1.11]；OR = 0.93，95% CI = [0.71 - 1.21]）。我们的荟萃分析结果表明，低摄入量的ASs可能与较低的CRC风险相关。
